A clinical-stage biopharmaceutical company deploying its proprietary Helicon peptide platform to drug historically undruggable cancer targets, including intracellular transcription factors long considered inaccessible to conventional modalities.
A clinical-stage biopharmaceutical company deploying its proprietary Helicon peptide platform to drug historically undruggable cancer targets, including intracellular transcription factors long considered inaccessible to conventional modalities.
